CRT grants exclusive license to Genentech to patent portfolio of an oncology target

Cancer Research Technology (CRT) announced today that it has entered into a license agreement granting Genentech, Inc. (NYSE: DNA) exclusive worldwide rights to its patent portfolio covering an oncology target discovered in the Molecular Oncology Laboratory (Oxford) of Cancer Research UK.

  • 20 July 2004

This oncology target was validated through collaboration between Cancer Research UK and CRT's Development Laboratory. Genentech plans to evaluate the potential of protein therapeutics directed to this target.  Harpal Kumar, CEO of CRT, commented, "CRT is delighted to have completed its first licensing partnership with Genentech for a therapeutic target. This partnership further exemplifies CRT's role in bringing benefit to cancer patients by facilitating the development of early-stage opportunities and forming partnerships between cancer researchers and industry to accelerate the development of new therapies. We believe that Genentech is the ideal partner to accelerate this therapeutic opportunity towards the clinic."

Related content

Two woman speak to each other on an inside balcony, with the photo taken from the floor

Our partnerships

Cancer Research Horizons partners across the fields of academia, industry, drug discovery and investors.

Scientist wearing a white lab coat and goggle looking at some equipment.

Drug discovery and development

We identify, develop and commercialise promising ideas into successful cancer therapeutics, diagnostics and enabling technologies.

Woman speaking to man

Partners

We de-risk innovation by turning promising science into high-value assets. Partner with us for access to our extensive network and portfolio.